Enter your username/e-mail and your new password will be send to you.
| Description | Fleming is non-profit research organisation that operates under the supervision of the General Secretariat for Research and Technology of the Hellenic Ministry of Education. It was established in 1998 and today is actively involved in cutting edge research in biomedical sciences. Integral to the Center's research activities are several platforms of genetic permutation in the mouse and their application in human disease modeling. Fleming participates in numerous EC FP6 and FP7 projects using the mouse as a research tool and has extensive interations with the biotech and pharmaceutical industry. Fleming currently consists of 14 highly competitive groups active in the areas of disease modelling, transgenic and conditional mutagenesis in the mouse, post-transcriptional regulation of gene expression, inter- and intra-cellular signalling and functional genomics. The Center is internationally recognized for its projects in translational research, and focuses on pathway, target and biomarker identification and validation, preclinical evaluation of therapeutics in animal models and novel drug development and screening . The Center's major goal is to support excellent research with a focus on innovation. Over the last decade Fleming has established state-of-the-art facilities that offer services for translational research to the Center internally, but also to researchers and companies in Greece and abroad. These include the Animal House (currently Greece's largest), as well as Units for Transgenesis and Cryopreservation, Genomics, Proteomics, Flow cytometry, Histopathology, and BioIT. Fleming has recently been invited to submit a plan for a 3.9Million euro grant to establish a local integrated infrastructure in the context of the ESFRI infrastructure INFRAFRONTIER, named Infrafrontier-GR. Infrafrontier-GR aims to provide an advanced platform for specialised phenotyping of mouse models of disease towards novel target identification and innovative drug development. The Infrastructure will build on the Center's already operating facilities for animal housing, transgenesis, archiving and phenotyping to provide easy access to mouse models and to facilitate their dissemination and exploitation within the Greek research community and abroad. Furthermore, Infrafrontier-GR will provide specialist secondary phenotyping services using advanced technological platforms, initially in the field of immunology and cancer, as well as in other disease areas, and is expected to enhance the discovery and innovation potential of the Greek research and industrial environment. In the context of its technology transfer and innovation activities, in 2006 the Center established a highly successful spin-off company, Biomedcode Hellas SA, a CRO that provides full preclinical drug evaluation services to the pharmaceutical industry using a unique collection of proprietary mouse models of human inflammatory diseases. Fleming costitutes a prime example of regional smart specialisation, achieving high levels of growth based on efficient innovation in areas of excellence and specialisation. |
| URL | http://www.fleming.gr/ |
| Status | Operational (2005 - 2012) Being upgraded (2012 - 2015) |
| Scientific Domains | Biological and Medical Sciences |
| RI Categorization | Databases |
| Location | Fleming 34, Vari-Athens, 16672, Attica, Greece |
| MERIL URL | http://portal.meril.eu/meril/view/facilitys/15020 |
